Morphine News and Research

Latest Morphine News and Research

FDA approves Endo’s BELBUCA (buprenorphine) buccal film for use in patients with chronic pain

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, and BioDelivery Sciences International, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved BELBUCA (buprenorphine) buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

28 Oct 2015

Drug that relieves opioid-induced constipation may help some cancer patients live longer

Patients with advanced cancers who took a drug designed to relieve constipation caused by pain killers lived longer and had fewer reports of tumor progression than cancer patients who did not receive the drug, according to results presented October 27 at the 2015 meeting of the American Society of Anesthesiologists in San Diego. This is the first study in humans to associate opioid blockade with improved survival.

28 Oct 2015

New research shows nicotine increases codeine-induced analgesia

According to new research in rat models, nicotine use over time increases the speed that codeine is converted into morphine within the brain, by increasing the amount of a specific enzyme. It appears smokers' brains are being primed for a bigger buzz from this common pain killer - which could put them at a higher risk for addiction, and possibly even overdose.

19 Oct 2015

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

BioDelivery Sciences International, Inc. announced that the U.S. Food and Drug Administration has approved the company's Supplemental New Drug Application (sNDA) for a manufacturing specification change for BUNAVAIL (buprenorphine and naloxone) buccal film (CIII).

15 Oct 2015

AcelRx Pharmaceuticals initiates ARX-04 Phase 3 study in emergency room patients with acute pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute and breakthrough pain, today announced the initiation of an open-label Phase 3 study (SAP302) of ARX-04 for the treatment of adult patients who present in the emergency room with moderate-to-severe acute pain associated with trauma or injury.

6 Oct 2015

New guideline on the use of prescription medications for treatment of opioid addiction

Medications play an important role in managing patients with opioid use disorders, but there are not enough physicians with the knowledge and ability to use these often-complex treatments.

25 Sep 2015

Premature infants in intensive care units exposed to a great deal of pain

Premature infants receiving intensive care are exposed to a great deal of pain, and this pain causes damage to the child. Despite this half of the infants admitted to neonatal intensive units will not receive any pain relief, according to a new European study published today in The Lancet Respiratory Medicine.

24 Sep 2015

TSRI study reveals key morphine regulator that may help develop less-addictive pain medications

Once used in the 18th century as currency to reverse the trade imbalance between China and Britain, opiates that contain morphine have been misunderstood almost continually ever since.

23 Sep 2015

BioDelivery Sciences and Endo present Phase 2 data on buprenorphine HCl buccal film in patients with chronic pain

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, and BioDelivery Sciences International, Inc. today presented data from a Phase 2 study for the investigational drug buprenorphine HCl buccal film utilizing BDSI’s patented BioErodible MucoAdhesive (BEMA) drug delivery technology.

11 Sep 2015

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing and commercializing innovative pain treatments, today announced the launch of OXAYDO (oxycodone HCI, USP) tablets -CII in the United States.

9 Sep 2015

Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Vernalis Therapeutics Inc., a subsidiary of Vernalis plc, today announced that Tuzistra XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral suspension, CIII (DEA Schedule III) is now available to adult patients and physicians in the United States.

8 Sep 2015

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing, and commercializing innovative pain treatments, today announced that researchers will be presenting scientific data on SPRIX (ketorolac tromethamine) Nasal Spray, Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development, at PainWeek 2015 to be held September 8 to 12 in Las Vegas, Nevada.

1 Sep 2015

Children's Hospital Los Angeles successfully implants Melody Transcatheter Pulmonary Valve in child actor

Cardiologists from Children's Hospital Los Angeles successfully implanted a Melody Transcatheter Pulmonary Valve in child actor Max Page, the boy who made headlines playing mini Darth Vader in a 2011 Super Bowl ad for Volkswagen.

28 Aug 2015

Researchers evaluate use of pharmacy-based naloxone education and distribution to fight opioid overdoses

In response to the growing opioid crisis, several states, including Massachusetts and Rhode Island, have granted pharmacists the authority to provide naloxone rescue kits without a prescription to at-risk patients. This model of pharmacy-based naloxone (PBN) education and distribution is one of the public health strategies currently being evaluated at hundreds of pharmacies in both states to determine the impact on opioid overdose death rates.

25 Aug 2015

Growing availability of heroin changing the face of opiate addiction in the U.S.

The growing availability of heroin, combined with programs aimed at curbing prescription painkiller abuse, may be changing the face of opiate addiction in the U.S., according to sociologists.

18 Aug 2015

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

United Therapeutics Corporation announced today that the European Commission (EC) has granted Marketing Authorisation for Unituxin (dinutuximab) for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT).

17 Aug 2015

Opioids produced by yeast; revealing the potential for cheaper pain relief

Researchers at Stanford University have genetically engineered yeast so it produces hydrocodone, a semi-synthetic opioid analgesic used in the United States for relief of moderate to severe pain.

14 Aug 2015

BDSI announces FDA approval of sNDA for new formulation of ONSOLIS (fentanyl buccal soluble film) CII

BioDelivery Sciences International, Inc. announced the approval by the U.S. Food and Drug Administration of a Supplemental New Drug Application (sNDA) for a new formulation of ONSOLIS (fentanyl buccal soluble film) CII for the management of breakthrough pain in patients with cancer who are opioid tolerant.

13 Aug 2015

Egalet declares pricing of underwritten public offering of common stock

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a public offering price of $11.25 per share.

28 Jul 2015

CU-Boulder study reveals how and when placebo effect works

You don't think you're hungry, then a friend mentions how hungry he is or you smell some freshly baked pizza and whoaaa, you suddenly feel really hungry. Or, you've had surgery and need a bit of morphine for pain. As soon as you hit that button you feel relief even though the medicine hasn't even hit your bloodstream.

25 Jul 2015

Morphine News and Research

Latest Morphine News and Research

FDA approves Endo’s BELBUCA (buprenorphine) buccal film for use in patients with chronic pain

Drug that relieves opioid-induced constipation may help some cancer patients live longer

New research shows nicotine increases codeine-induced analgesia

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

AcelRx Pharmaceuticals initiates ARX-04 Phase 3 study in emergency room patients with acute pain

New guideline on the use of prescription medications for treatment of opioid addiction

Premature infants in intensive care units exposed to a great deal of pain

TSRI study reveals key morphine regulator that may help develop less-addictive pain medications

BioDelivery Sciences and Endo present Phase 2 data on buprenorphine HCl buccal film in patients with chronic pain

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Children's Hospital Los Angeles successfully implants Melody Transcatheter Pulmonary Valve in child actor

Researchers evaluate use of pharmacy-based naloxone education and distribution to fight opioid overdoses

Growing availability of heroin changing the face of opiate addiction in the U.S.

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

Opioids produced by yeast; revealing the potential for cheaper pain relief

BDSI announces FDA approval of sNDA for new formulation of ONSOLIS (fentanyl buccal soluble film) CII

Egalet declares pricing of underwritten public offering of common stock

CU-Boulder study reveals how and when placebo effect works

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Morphine News and Research

Latest Morphine News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in